niacinamide has been researched along with Fever in 8 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well." | 7.83 | A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. ( Chen, X; Cui, T; Diao, X; Huang, S; Sun, J, 2016) |
| "The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC)." | 7.83 | Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2016) |
| "To evaluate the safety and efficacy of combined therapy with transarterial chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with portal venous tumour thrombus (PVTT)." | 7.80 | Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. ( Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014) |
| "Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well." | 3.83 | A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. ( Chen, X; Cui, T; Diao, X; Huang, S; Sun, J, 2016) |
| "The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC)." | 3.83 | Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2016) |
| "To evaluate the safety and efficacy of combined therapy with transarterial chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with portal venous tumour thrombus (PVTT)." | 3.80 | Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. ( Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014) |
| "Sorafenib is a multi-kinase inhibitor currently approved in Japan for unresectable and/or metastatic renal cell carcinoma and unresectable hepatocellular carcinoma." | 3.79 | Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. ( Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, T | 1 |
| Li, XS | 1 |
| Xie, QK | 1 |
| Wang, JP | 1 |
| Li, W | 1 |
| Wu, PH | 1 |
| Zhao, M | 1 |
| Cui, T | 1 |
| Diao, X | 1 |
| Chen, X | 1 |
| Huang, S | 1 |
| Sun, J | 1 |
| Kuzuya, T | 1 |
| Ishigami, M | 1 |
| Ishizu, Y | 1 |
| Honda, T | 1 |
| Hayashi, K | 1 |
| Ishikawa, T | 1 |
| Nakano, I | 1 |
| Goto, H | 1 |
| Hirooka, Y | 1 |
| Horiuchi-Yamamoto, Y | 1 |
| Gemma, A | 1 |
| Taniguchi, H | 1 |
| Inoue, Y | 1 |
| Sakai, F | 1 |
| Johkoh, T | 1 |
| Fujimoto, K | 1 |
| Kudoh, S | 1 |
| Lee, EJ | 1 |
| Wu, TS | 1 |
| Chang, GL | 1 |
| Li, CY | 1 |
| Chen, TY | 1 |
| Lee, MY | 1 |
| Chen, HY | 1 |
| Maynard, KI | 1 |
| Iakimova, K | 1 |
| Micheva, M | 1 |
| Bantutova, I | 1 |
| Ovcharov, R | 1 |
| Lwoff, A | 1 |
| Coper, H | 1 |
| Lison, H | 1 |
| Rommelspacher, H | 1 |
| Schulze, G | 1 |
| Strauss, S | 1 |
8 other studies available for niacinamide and Fever
| Article | Year |
|---|---|
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2014 |
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacin | 2016 |
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Fe | 2016 |
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Co | 2013 |
Delayed treatment with nicotinamide inhibits brain energy depletion, improves cerebral microperfusion, reduces brain infarct volume, but does not alter neurobehavioral outcome following permanent focal cerebral ischemia in Sprague Dawley rats.
Topics: Adenine; Adenosine Triphosphate; Animals; Behavior, Animal; Brain; Brain Chemistry; Cerebrovascular | 2006 |
[Inhibition of morphine hyperthermia, induced by nicotinamide].
Topics: Animals; Fever; Male; Morphine; Niacinamide; Rats; Rats, Inbred Strains | 1989 |
From protozoa to bacteria and viruses. Fifty years with microbes (André Lwoff).
Topics: Bibliographies as Topic; Ciliophora; Crustacea; Eukaryota; Eye; Fever; France; Growth Substances; He | 1971 |
The influence of adrenergic receptor-blocking agents, amphetamine, and 6-aminonicotinamide on thermoregulation.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amines; Amphetamine; Animals; Body Temper | 1971 |